Grace Li

AACR Virtual Annual Meeting I presents new data on cancer biology, treatment, screening, risk reduction

Brief points covered in the America Association for Cancer Research (AACR) Virtual Annual Meeting I held on April 27-28th: -Treating BRAF-Positive Melanoma by adding checkpoint inhibitor Tecentriq (atezolizumab) to a combination of two targeted drugs Zelboraf (vemurafenib) and Cotellic (cobimetinib) -PARP Inhibitor (targeted drugs that inhibit DNA damage repair) are…...

Read more

Link between Children with Cancer and COVID-19

May 16th, 2020 A study indicates that children with cancer are not at increased risks of severe cases of COVID-19, and researchers find that Medicaid expansion was associated with reduced cancer deaths. Read more at: https://www.cancertodaymag.org/Pages/cancer-talk/May-15-The-Week-in-Cancer-News.aspx...

Read more

FDA Approves Pemazyre (Pemigatinib) for Bile Duct Cancer

The US Food and Drug Administration (FDA) approved the first targeted therapy for bile duct cancer. Pemazyre (pemigatinib) is for adults with advanced bile duct cancer whose cancer has grown after at least one previous chemotherapy treatment and whose tumors have a mutation in the FGFR2 gene. Full information at: https://www.cancer.org/latest-news/fda-approves-pemazyre-pemigatinib-for-bile-duct-cancer.html...

Read more

FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer

The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments. Triple-negative breast cancer is called that because the cancer cells don’t have estrogen or progesterone receptors and also…...

Read more

Common Questions About the New Coronavirus Outbreak

Cancer patients are among those at high-risk of serious illness from an infection because their immune systems are often weakened by cancer and its treatments. Although most people who were treated for cancer in the past (especially if it was years ago) are likely to have normal immune function, each…...

Read more

A combo of fasting plus vitamin C is effective for hard-to-treat cancers, study shows

Researchers have discovered that a fasting-mimicking diet could be more effective at treating some types of cancer when combined with vitamin C. In studies on mice, researchers found that the combination delayed tumor progression in multiple mouse models of colorectal cancer; in some mice, it caused disease regression. For full…...

Read more

Boosting Dendritic Cells Helps the Immune System Find Pancreatic Cancer

Dendritic cells are part of the immune system’s first line of defense against cancer and infections and is often used in immunotherapy to treat lung cancer. The question in study here is why immunotherapy tends to be more effective in treating lung cancer than pancreatic cancer and the answer may,…...

Read more

PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows

Traditionally, the most commonly used method of prostate cancer imaging is the CT scan or bone scan. The new use of PSMA PET-CT proved to be substantially more likely to detect metastatic tumors in men with prostate cancer than the standard imaging approach. The FDA hasn’t approached any PSMA-targeted imaging…...

Read more

For Women with Breast Cancer, Regular Exercise May Improve Survival

A new study conducted by Rikki Cannioto, Ph.D., Ed.D., of Roswell Park Comprehensive Cancer Center in Buffalo, NY adds to the existing evidence linking physical activity with longer survival in women diagnosed with high-risk breast cancer. Women with breast cancer who met the minimum physical activity guidelines both before diagnosis…...

Read more

COVID-19: Fighting viruses with viruses

Dr. Alan Parker’s team at Cardiff University is studying how we can pit one viral threat against another and use viruses to destroy cancer cells. The idea of immunotherapy is not completely new, but the idea of utilizing the COVID-19 virus to hung and destroy cancer cells and novel. See…...

Read more